Optiscan Imaging Limited (AU:OIL) has released an update.
Optiscan Imaging Limited has reported a productive quarter with key advancements, including a $3 million Australian government grant for developing an AI-enabled endomicroscope, progress on multiple medical device projects, and strategic expansion with the establishment of a US office and appointments to enhance FDA dealings. The company is focusing on innovative medical imaging technologies, such as a new clinical device for breast cancer surgery and a digital pathology device, along with a cloud-based telepathology platform, poised for future integration.
For further insights into AU:OIL stock, check out TipRanks’ Stock Analysis page.
